Kuros Biosurgery, a developer of combination products for trauma, spine and wound indications, has enrolled first patient for its European clinical trial with a dural sealant - KUR-023.
The study is a multi-center, single arm designed to assess the safety and efficacy of the dural sealant product candidate.
KUR-023 is a spray delivered synthetic hydrogel-based sealant which uses Kuros’ synthetic technology.
KUR-023 is delivered from a double barrelled syringe with a mixing spray tip and the applied gel adheres strongly to the dural surface and be able to withstand cerebral pressures in excess.
The primary endpoint refers to the prevention of intraoperative leakage with secondary endpoints related to safety and further effectiveness assessment.
Kuros Biosurgery CEO Didier Cowling said KUR-023 is the based on their synthetic technology to have entered into clinical studies and they look forward to report the results of this study in the near future.